

PHARMACOLOGICAL REVIEWS

Editorial Board

OTTO KRAYER, *Chairman*

HARRY EAGLE

ERIK JACOBSEN

U. S. V. EULER

MARK NICKERSON

ALFRED GILMÁN

DOUGLÁS S. RIGGS

H. R. ING


MARTHE VOGT

MILES WEATHERALL

VOLUME 7

1955

BALTIMORE, MARYLAND



CONTENTS OF VOLUME 7

NUMBER 1, MARCH 1955

Metabolism of the Mucopolysaccharides of Connective Tissue. ALBERT DORFMAN	1
Motion Sickness. HERMAN I. CHINN AND PAUL K. SMITH	33
Histochemistry—A Review. JONAS S. FRIEDENWALD	83
Models for the Study of the Contraction of Muscle and of Cell Protoplasm. WILHELM HASSELBACH AND ANNEMARIE WEBER	97
Action of Drugs on Carotid Body and Sings. C. HEYMANS	119

NUMBER 2, JUNE 1955


Physiological and Pharmacological Influences upon Intraocular Pressure. W. MORTON GRANT	143
The Pharmacology of Vascular Smooth Muscle. ROBERT F. FURCHGOTT	183
Pharmacology and Functions of the Mast Cells. JAMES F. RILEY	267
The Chemotherapy of Filarial Infections. FRANK HAWKING	279

NUMBER 3, SEPTEMBER 1955

A Survey of the Factors Controlling Thyroid Function, with Especial Reference to Newer Views on Antithyroid Substances. W. P. VANDERLAAN AND V. M. STORRIE	301
The Uncoupling of Oxidative Phosphorylation as a Mechanism of Drug Action. THEODORE M. BRODY	335
The Pharmacology of Sweating. WALTER C. RANDALL AND KAZUO K. KIMURA	365
The Metabolism and Toxicity of Methanol. OLUF RÖE	399

NUMBER 4, DECEMBER 1955

The Neurotoxins of <i>Clostridium botulinum</i> and <i>Clostridium tetani</i> . G. PAYLING WRIGHT	413
The Use and Limitations of Atropine for Pharmacological Studies on Autonomic Effectors. N. AMBACHE	467



INDEX

- Acetylcholine, effect on vascular smooth muscle, 209
local indirect vasoconstricting action, 246
nicotinic and muscarinic actions, 371
sweat gland response, 372
- Actomyosin, interactions with ATP, 98
- Adenosinediphosphate, *see* ADP
- Adenosinemonophosphate, *see* AMP
- Adenosinetriphosphate, *see* ATP
- Adenylic acid derivatives, effect on vascular smooth muscle, 209
- ADP, changes in concentration, influence on muscle contraction, 104
- Adrenal corticoids, sweat gland response, 390
- Alimentary tract muscles, effect of atropine, 470
- Alkali ions, role in muscle contraction, 108
- Ambache, N. Use and limitations of atropine for pharmacological studies on autonomic effectors, 467
- Amino group reagents, role in muscle contraction, 112
- Aminothiazole, incidence of toxic effects during clinical use, 324
- AMP, changes in concentration, influence on muscle contraction, 104
- Amyl nitrite, influence on intraocular pressure, 170
- Anesthetic, local, influence on intraocular pressure, 171
- Antagonism, irreversible competitive, kinetics of development of and recovery from, 223
reversible competitive, kinetics of development of and recovery from, 218
- Antagonists, specific, effect on vascular smooth muscle, 211
relative specificity, 225
use in studies on vascular pharmacology and physiology, 226
- Antibiotics, role in uncoupling phosphorylation from oxidation, 346
- Antidromic phenomena, effect of atropine, 488
- Antihistamines, value in motion sickness, 61
- Antimonials, action on filarial infections, 289
- Antithyroid agents; incidence of serious toxic effects and death during clinical use, 325
- substances, mode of action, 310
- Aqueous humor, inflow, 150
outflow, 151
rate of flow, determination by means of tracer substances, 162
vessels containing, observations, 161
- Argemone oil, influence on intraocular pressure, 173
- Arsenicals, action on filarial infections, 291
- Atropine, effect on antidromic phenomena, 488
on bladder muscles, 484
on ganglia, 489
on peristalsis, 475
on response of motor neurones to nicotine stimulation, 475
on response to vagal stimulation, species differences, 470
on salivary glands, 486
on skeletal muscle, 489
resistance by nerve effect, 469
response of muscular layers of intestine, 479
susceptibility to, as criterion of cholinergic transmission, 469
sweat gland response, 383
use and limitations for pharmacological studies on autonomic effectors, 467
- value in classification of intestinomotor drugs, 483
in motion sickness, 55
- ATP, changes in concentration, influence on muscle contraction, 102
interactions with actomyosin, 98
- Azide, effect on vascular smooth muscle, 210
- Belladonna alkaloids, value in motion sickness, 64
- Binders, value in motion sickness, 52
- Bladder muscles, effect of atropine, 484
- Blocking agents, effects on vascular smooth muscle, 211
- Blood-aqueous humor barrier, estimation of permeability, 162
- Blood distribution, alterations, role in motion sickness, 49
- vessels, nature of terminal efferent innervation, 187
orientation of muscle, 186

- Botulinum toxin, action on enzyme systems, 431
 culture filtrates, presence of other "toxins," 424
 evidence provided regarding neurology of intestine, 480
 fixation and duration of action, 433
 immunological types, 416
 lethality for poikilothermic animals, 431
 pathogenicity of different types for different animal species, 417
 potentiation by serum and other materials, 423
 purification, 421
 resistance to heat and other agents, 420
 site of action, 424
- Botulism, action of anticholinesterase drugs; general features, 432
- Brody, Theodore M. Uncoupling of oxidative phosphorylation as mechanism of drug action, 335
- Caffeine, role in muscle contraction, 113
 Calcium ion, role in muscle contraction, 106
 Carbachol, sweat gland response, 381
 Carbimazole, incidence of toxic effects during clinical use, 325
- Cardiac glycosides, role in muscle contraction, 112
- Carotid body chemoreceptors, pharmacological actions on, 123
 physiological properties, 120
- Carotid sinus pressoreceptors, action of drugs, 130
- Cell metabolism, role of oxidative phosphorylation, 336
 protoplasm, contraction, models for study, 97
- Central nervous depressants, value in motion sickness, 58
 depressing drugs, influence on intraocular pressure, 171
 stimulating drugs, influence on intraocular pressure, 171
- Cerebellum, role in motion sickness, 46
 Cerebrum, role in motion sickness, 48
 Chinn, Herman L., and Paul K. Smith. Motion sickness, 33
- Chitosamine, *see* glucosamine
- Chlorpromazine, value in motion sickness, 54
- Cholinergic motor neurones; predominance in gut, supporting evidence, 481
 transmission, susceptibility to atropine as criterion, 469
- Chondrosamine, *see* Galactosamine
- Clostridium botulinum*, neurotoxins, 413
tetani, neurotoxins, 413
- Cocaine, potentiating action, 236
- Cyanine compounds, action on filarial infections, 292
- Diamox, influence on intraocular pressure, 172
- Dietary measures, value in motion sickness, 52
- Diethylcarbamazine, clinical uses, 288
 mode of action, 283
 pharmacology and distribution, 287
 relation of structure to activity, 283
 toxicity, 286
- Diffusible components, difficulties of localization in analysis *in situ*, 89
- Diffusion of reaction product, problem in analysis *in situ*, 91
- Diphenhydramine, value in motion sickness, 53
- Dorfman, Albert. Metabolism of mucopolysaccharides of connective tissue, 1
- Drugs for protection against motion sickness, methods of testing, 53
- Electrical stimulation, role in uncoupling phosphorylation from oxidation, 355
- Emetic trigger zone, role in motion sickness, 47
- Enzyme localization, problem of possible diffusion in analysis *in situ*, 90
 role in drug action, 335
- Eosinophil, function in histamine problem, 272
- Ephedrine, local indirect vasoconstricting action, 246
 potentiating action, 238
- Epinephrine, effect on vascular smooth muscle, 200
 potentiation of responses to, possible source of error in studies, 233
 sweat gland response, 386
- Ethyl alcohol, effects on methanol poisoning, 404
- Eye, cannulated, measurement, 159
 goniometry, 163
 intact, tonometry, 160
 tonography, 160
- 5-Hydroxytryptamine, effect on vascular smooth muscle, 207
 local indirect vasoconstricting action, 248

- Filarial infections, biology, 279
 chemotherapy, history, 282
 reaction to chemotherapy, 283
- Fixed tissue components, difficulties of
 localization in analysis *in situ*, 87
- Friedenwald, Jonas S. Histochemistry—a
 review, 83
- Furchtgott, Robert F. Pharmacology of
 vascular smooth muscle, 183
- Furtrethonium, sweat gland response, 382
- Galactosamine, metabolism, 6
- Ganglia, effect of atropine, 489
- Ganglionic blocking drugs, influence on
 intraocular pressure, 170
 sweat gland response, 385
- Glaucoma, classification, 155
 pathogenesis, 155
- Glucosamine, metabolism, 6
- Glucuronate acid, metabolism, 3
- Grant, W. Morton. Physiologic and pharma-
 cologic influences upon intraocular
 pressure, 143
- Graves' disease, value of antithyroid
 therapy, 314
- Ground substance, definitions, 2
- Halophenois, role in uncoupling phosphory-
 lation from oxidation, 350
- Hasselbach, Wilhelm, and Annemarie
 Weber. Models for study of contrac-
 tion of muscle and of cell proto-
 plasm, 97
- Hawking, Frank. Chemotherapy of filarial
 infections, 279
- Heparin, location and function in mast cell,
 270
- Heymans, C. Action of drugs on carotid
 body and sinus, 119
- Hexene-ol, sweat gland response, 382
- Hexosamines, metabolism, 6
 phosphorylation, 8
- Histamine, effect on vascular smooth
 muscle, 208
 influence on intraocular pressure, 170
 location and function in mast cell, 270
- Histochemistry, analysis *in situ* as method
 of approach, 87
 mechanical separation as method of ap-
 proach, 84
 micro-dissection and micro-analysis as
 method of approach, 85
 review, 83
- Hormones, effects on metabolism of muco-
 polysaccharides, 22
 influence on intraocular pressure, 172
- Hyaluronidases, action, 12
- Hyoscine, value in motion sickness, 53
- Hypertension, effect on vascular smooth
 muscle, 207
- Hyperthyroidism, prognosis, influence of
 antithyroid substances, 326
 substances available for treatment, 315
- Hypnotic drugs, role in uncoupling phos-
 phorylation from oxidation, 341
- Hypoxia, role in motion sickness, 49
- Inosinetriphosphate, *see* ITP
- Intestine, muscular layers, response to
 atropine, 479
- neurology, contribution to understanding
 provided by botulinum toxin, 480
- Intestinomotor drugs, classification by
 means of atropine, 483
- Intraocular pressure, anatomic considera-
 tions, 146
 hydrodynamic considerations, 143
 influence of autonomic drugs, 164
 of drugs, methods for evaluating, 159
 of non-autonomic drugs, 170
 pathologic aspects, 154
 variation, 157
 pharmacologic influences, 164
 physiologic aspects, 150
 variations, 152
- Iodide ion, role in thyroid function, 302
- Iodothiouracil, incidence of toxic effects
 during clinical use, 324
- Isopropylarterenol, effect on vascular
 smooth muscle, 204
- ITP, changes in concentration, influencé
 on muscle contraction, 104
- Kimura, Kazuo K., *see* Randall, 365
- Kinétosis, *see* Motion sickness
- Lergigan, value in motion sickness, 53
- Magnesium ion, role in muscle contraction,
 105
- Mast cells, biological significance, 273
 morphology and distribution, 267
 pharmacology, 268
- Metal complexing agents, role in muscle
 contraction, 108
- Methacholine, sweat gland response, 381
- Methanol, absorption and distribution in
 organism, 399

- Methanol—Continued
 elimination by means of oxidation, 400
 in expired air, 399
 intoxication, hypotheses concerning pathogenesis, 409
 treatment, 405
 lethal doses, 402
 oxidation, mechanism, 401
 metabolism, 399
 poisoning, effects of ethyl alcohol, 404
 pathological findings, 403
 symptoms, 402
 toxic doses, 402
- Methimazole, incidence of toxic effects during clinical use, 321
- Methylthiouracil, incidence of toxic effects during clinical use, 319
- Molecular mechanism of contraction, substances and active groups of protein participating, 101
- "Monoamine oxidase hypothesis" of potentiation of responses to epinephrine and norepinephrine by various drugs, 234
- Motion sickness, drugs for protection, value, 53
 etiology, 41
 incidence, 35
 preventive drugs, action on cerebellum, 69
 action on medulla, 70
 undesirable side effects, 65
 vestibular action, 68
 prophylactic and therapeutic measures, 51
 relationship to vestibular stimulation, 43
 review of history, 33
 role of central nervous pathway, 46
 of non-labyrinthine stimuli, 48
 selection of persons resistant, methods, 39
 symptoms, 33
- Mucopolysaccharides, biosynthesis in streptococci, 10
 metabolism in mammals, 16
 of connective tissue, metabolism, 1
- Muscle, contraction, models for study, 97
see also under Vascular smooth muscle
- Nicotine, local indirect vasoconstricting action, 246
 stimulation, response of motor neurones, effect of atropine, 475
see sweat gland response, 372
- Nitrates, organic, effect on vascular smooth muscle, 210
- Nitrites, effect on vascular smooth muscle, 210
- Nitrophenols, role in uncoupling phosphorylation from oxidation, 350
- Norepinephrine, effect on vascular smooth muscle, 203
 potentiation of responses to, possible source of error in studies, 233
- Ocular hypotony, nature of problem, 154
- Orthophosphate, role in muscle contraction, 105
- Oxidative phosphorylation, role in cell metabolism, 336
- Paraaminosalicylic acid, antithyroid action, 310
- Parasympathetic blocking drugs, sweat gland response, 383
- Parasympatholytic drugs, influence on intraocular pressure, 166
 value in motion sickness, 55
- Parasympathomimetic drugs, influence on intraocular pressure, 164
- Peristalsis, effect of atropine, 475
- Phenothiazine, antithyroid action, 311
- Phenylbutazone, antithyroid action, 311
- Phosphorylation uncoupling agents, 341
- Physical therapy, value in motion sickness, 52
- Physostigmine, sweat gland response, 379
- Pilocarpine, sweat gland response, 375
- Piperazine derivatives, action on intestinal nematodes, 285
- Pitressin, effect on vascular smooth muscle, 207
- Pituitary gland, relationship to thyroid gland, 301
- Polyphosphates, inorganic, role in muscle contraction, 104
- Propylthiouracil, incidence of toxic effects during clinical use, 320
- Protein participating in molecular mechanism of contraction, substances and active groups, 101
- Psychic factors, role in motion sickness, 49
- Psychotherapy, value in motion sickness, 52
- Quinine, role in muscle contraction, 113
- Randall, Walter C., and Kazuo K. Kinjura, Pharmacology of sweating, 365

- Receptor hypothesis, development, 197
theory for non-competitive antagonisms
and "irreversible competitive antagonism," 214
for "reversible competitive antagonism" and its application, 211
- Resorcinol, antithyroid action, 310
- Röe, Oluf. Metabolism and toxicity of methanol, 399
- Riley, James F. Pharmacology and functions of mast cells, 267
- Salicylates, role in uncoupling phosphorylation from oxidation, 349
- Salivary glands, effect of atropine, 486
- Sanguinarine, influence on intraocular pressure, 173
- Scopolamine, value in motion sickness, 55
- Skeletal muscle, effect of atropine, 489
- Smith, Paul K., *see* Chinn, 33
- Smooth muscle, *see under* Vascular smooth muscle
- Storrie, V. M., *see* VanderLaan, 301
- Sudorific agents, comparative effectiveness, 389
- Sulphydryl reagents, role in muscle contraction, 109
- Sulfonic groups, substances containing, role in muscle contraction, 112
- Suramin, action on filarial infections, 293
- Sweat glands, response to various drugs, 372
structure and function, 365
sympathetic cholinergic innervation, 368
- Sweating experiments in animals and man, interpretation, 367
- Sympatholytic drugs, influence on intraocular pressure, 169
- Sympathomimetic amines, effect on vascular smooth muscle, 205
local indirect vasoconstricting action, 246
potentiating action, 238
drugs, influence on intraocular pressure, 167
- Tachyphylactic phenomena, relation to local indirect vasoconstricting action of certain drugs, 249
- Temperature elevation, role in motion sickness, 49
- Tetanus, general features, 434
toxin, lethality, effect of route of injection, 439
- lethality for poikilothermic animals, 454
minimum lethal dose, difficulties in determination, 436⁵
- pathogenicity for various animal species, 438
- potentiation by serum and other agents, 437
- protection against, by prior injections of tetanus toxoid, 456
- purification, 435
- site of action, 440
- spread from depot site in tissues, 446
- Tetracycline drugs, antimicrobial activity, role of uncoupling, 348
- Thiobarbital, incidence of toxic effects during clinical use, 324
- Thiocyanate, role in thyroid function, 309
- Thiouracil, antithyroid function, 312
- Thiourea, incidence of toxic effects during clinical use, 323
- Thyroid gland, relationship to pituitary gland, 301
hormone, role in thyroid function, 312
role in uncoupling phosphorylation from oxidation, 352
- Tryptamine, local indirect vasoconstricting action, 248
- Tyramine, local indirect vasoconstricting action, 246
- Uncoupling, methods of studying, 337
- Urea, role in muscle contraction, 112
- Vagal stimulation, effect of atropine on response, species differences, 470
- VanderLaan, W. P., and V. M. Storrie.
Survey of factors controlling thyroid function, with especial reference to newer views on antithyroid substances, 301
- Vascular smooth muscle, biochemistry, 195
drug action, local potentiation, 229
electrophysiology, 188
- local indirect action of certain drugs, 244
responding to drugs, localization, 185
response to changes in internal pressure, 193
to electric stimulation, 193
to light, 194
to mechanical stimulation, 192
to various drugs, 200
- tone, phasic variations, 189

- Vasoconstricting action of certain drugs, relation to tachyphylactic phenomena, 249
- Vestibular stimulation, relationship to motion sickness, 43
- Visceral displacement, role in motion sickness, 49
- Visual stimuli, role in motion sickness, 48
- Vitamins, value in motion sickness, 60
- Weber, Annemarie, *see* Hasselbach, 97
- Wright, G. Payling, Neurotoxins of *Clostridium botulinum* and *Clostridium tetani*, 413
- Wuchereria bancrofti*, eradication by diethylcarbamazine, 289
- malayi*, eradication by diethylcarbamazine, 289